LA-419, a nitric-oxide donor for the treatment of cardiovascular disorders

Current Opinion in Investigational Drugs

Volumn 10, Issue 3, 2009, Pages 276-285

  Megson, I L ^a   Leslie, S J ^b  

^a UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^b RAIGMORE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LA 419; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; SILDENAFIL; UNCLASSIFIED DRUG; WO 0020420; WO 2005037842;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG METABOLISM; DRUG TOLERABILITY; ENTEROPATHY; GLAUCOMA; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HOT FLUSH; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATENT; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT CONTRAINDICATION;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DRUG TOLERANCE; FIBRINOLYTIC AGENTS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOSORBIDE DINITRATE; MYOCARDIAL ISCHEMIA; NITRIC OXIDE DONORS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 62249107469     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 202291 The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Furchgott RF, Zawadzki JV NATURE 1980 288 5789 373-376
2. 202292 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Palmer RM, Ferrige AG, Moncada S NATURE 1987 327 6122 524-526
3. 239043 Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG J CLIN INVEST 1996 98 6 1465-1470
4. 310972 Mechanisms of pain in angina pectoris - A critical review of the adenosine hypothesis. Sylvén C CARDIOVASC DRUGS THER 1993 7 5 745-759
5. 471448 Nitric oxide donor drugs: Current status and future trends. Megson IL, Webb DJ EXPERT OPIN INVEST DRUGS 2002 11 5 587-601
6. 514528 Nitric oxide as cardiovascular therapy: New nitric oxide donors. Salas E SMI CONF - FUTURE OPPORTUNITIES INNOVATIVE THER CARDIOVASC DIS 2003 November 19-20
7. 514588 Future opportunities & innovative therapies for cardiovascular diseases - SMi Conference, London, UK. Mazucco RA IDDB MEETING REPORT 2003 November 19-20
8. 549764 A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Vilahur G, Segales E, Casani L, Badimon L THROMB HAEMOST 2004 91 5 1035-1043 •• Presents data from an early in vivo study of LA-419 in pigs. LA-419 demonstrated antiplatelet activity and inhibited platelet aggregation in a dose-dependent manner. Intraplatelet levels of cGMP increased immediately following the initiation of LA-419 treatment and remained above baseline levels throughout the treatment period. Importantly, significant changes in mean arterial pressure or heart rate were not observed following 10 days of treatment. However, aspartate aminotransaminase and alanine aminotransaminase levels were significantly increased at high doses of the drug.
9. 610749 NitroMed announces launch of BiDil for the treatment of heart failure in black patients; NitroMed announces BiDil pricing, BiDil patient assistance program; July 15th launch overview conference call. NitroMed Inc PRESS RELEASE 2005 July 01
10. 625211 Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M N ENGL J MED 2004 351 20 2049-2057
11. 801804 The nitric oxide donor LA 419 decreases brain damage in a focal ischemia model. Martinez-Murillo R, Fernandez AP, Serrano J, Rodrigo J, Salas E, Mourelle M, Martinez A NEUROSCI LETT 2007 415 2 149-153
12. 804967 Protein disulphide isomerase-mediated LA419-NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Vilahur G, Pena E, Padro T, Badimon L THROMB HAEMOST 2007 97 4 650-657 •• Presents data from an in vivo study of concomitant treatment with LA-419 and clopidogrel in pigs. Platelet deposition was significantly reduced by treatment with LA-419 alone compared with control; a greater reduction (significant versus LA-419 alone) was observed in animals treated with LA-419 plus clopidogrel. Collagen- and ADP-induced platelet aggregation was also significantly reduced.
13. 810287 A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. Zafar MU, Vilahur G, Choi BG, Ibanez B, Viles-Gonzalez JF, Salas E, Badimon JJ J THROMB HAEMOST 2007 5 6 1195-1200
14. 836716 Lacer company website and pipeline. COMPANY WORLD WIDE WEB SITE 2007 October 05
15. 862180 LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C HYPERTENSION 2007 50 6 1049-1056 • Presents data from an in vivo study of stenosis-induced experimental LVH in rats. LA-419 treatment significantly reduced the heart-to-body ratio and left ventricular diameter compared with control. These effects appeared to be related to the protection of endothelial NOS expression and to an increased interaction between endothelial NOS and the chaperone protein Hsp90.
16. 875991 The phase-I clinical trials on the LA-419 project have been successfully completed. Lacer SA PRESS RELEASE 2006 November 30
17. 923008 The nitric oxide donor LA-419 [S-(6-nitro-oxi-hexahydrofuro[3, 2-b]furan-3-1-il)thioacetate] prevents intestinal dysmotility, bacterial translocation, and inflammation in a rat model of enteritis. Porras M, Martin MT, Teran E, Mourelle M, Vergara P J PHARMACOL EXP THER 2008 324 2 740-748
18. 947120 LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling. Paulis L, Simko F HYPERTENSION 2007 50 6 1009-1011
19. 947126 The nitric oxide donor LA 419 decreases ischemic brain damage. Serrano J, Fernandez AP, Martinez-Murillo R, Alonso D, Rodrigo J, Salas E, Mourelle M, Martinez A INT J MOL MED 2007 19 2 229-236
20. 947127 Anti-thrombotic properties of a novel nitric oxide donor (LA-419) in a human model of thrombosis. Zafar MU, Vilahur G, Choi B, Salas E, Fuster V, Badimon J J AM COLL CARDIOL 2006 47 4 Suppl A 290A-291A
21. 947128 Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis. Hernandez MR, Tonda R, Arderiu G, Pino M, Serradell M, Escolar G EUR J CLIN INVEST 2005 35 5 337-342 •• Presents the first data on the ex vivo effects of LA-419 on blood derived from healthy human volunteers. Compared with control, LA-419 significantly reduced the interaction of platelets with the collagen surface, platelet interaction with a damaged vessel surface, and the cross-sectional area of the thrombus.
22. 969281 The antioxidant nitric oxide donor LA-419 protects isolated heart from ischemia-reperfusion injury. Mourelle M, Caracuel L, Gimenez F METHODS FIND EXP CLIN PHARMACOL 2008 30 Suppl 2 165
23. 969496 LA-419, a novel therapeutic candidate to prevent pulmonary hypertension and lung injury. Mourelle M, Gimenez F METHODS FIND EXP CLIN PHARMACOL 2008 30 Suppl 2 130
24. 973988 Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice. Carnicer R, Guillen N, Arbones-Mainar JM, Navarro MA, Guzman MA, Barranquero C, Arnal C, Gascon S, Acin S, Mourelle M, Osada J NAUNYN SCHMIEDEBERGS ARCH PHARMACOL 2008:doi:10.1007/s00210-008- 0377-5 • Presents data suggesting that LA-419 inhibited atherogenesis in an apolipoprotein-E-deficient mouse model. Lesion sizes were reduced in treated animals, an effect that was associated with reduced oxidative stress and decreased plasma triglyceride levels. Body weight gain and adipose tissue mass were also reduced compared with controls.
25. 974046 LA-419, a new nitric oxide donor, prevents pathological cardiac remodeling in pressure-overload rats via eNOS-pathway regulation. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle MI, Delgado C ACTA PHYSIOL 2007 190 Suppl 655 P65
26. 974149 Protein disulfide-isomerase mediates delivery of nitric oxide redox derivatives into platelets. Bell SE, Shah CM, Gordge MP BIOCHEM J 2007 403 2 283-288
27. 974152 Endothelial dysfunction: From molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Le Brocq M, Leslie SJ, Milliken P, Megson IL ANTIOXIDANT REDOX SIGNAL 2008 10 9 1631-1674
28. 974155 Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH et al N ENGL J MED 1986 314 24 1547-1552
29. 974157 Veterans administration cooperative study on vasodilator therapy of heart failure: Influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Flohr KH et al CIRCULATION 1987 75 5 Pt 2 IV49-IV54
30. 974158 The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Daiber A, Mulsch A, Hink U, Mollnau H, Warnholtz A, Oelze M, Munzel T AM J CARDIOL 2005 96 7B 25i-36i
31. 974161 Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Daiber A, Oelze M, Coldewey M, Kaiser K, Huth C, Schildknecht S, Bachschmid M, Nazirisadeh Y, Ullrich V, Mulsch A, Munzel T et al BIOCHEM BIOPHYS RES COMMUN 2005 338 4 1865-1874
32. 974166 New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Daiber A, Wenzel P, Oelze M, Munzel T CLIN RES CARDIOL 2008 97 1 12-20
33. 974171 Role of endogenous hydrogen peroxide in the development of nitrate tolerance. Ghatta S, Hemmer RB, Uppala S, O'Rourke ST VASCUL PHARMACOL 2007 46 4 247-252
34. 974184 Combating nitrate tolerance: A novel endogenous mechanism. Gutterman DD ARTERIOSCLER THROMB VASC BIOL 2007 27 8 1673-1676
35. 974274 The effect of oxidative stress on endothelium-dependent and nitric oxide donor-induced relaxation: Implications for nitrate tolerance. Hanspal IS, Magid KS, Webb DJ, Megson IL NITRIC OXIDE BIOL CHEM 2002 6 3 263-270
36. 974284 S-nitrosothiols for nitrate tolerance. Maxwell S, Megson I, Webb D LANCET 1999 354 9175 338-339
37. 974286 The enigma of nitroglycerin bioactivation and nitrate tolerance: News, views and troubles. Mayer B, Beretta M BR J PHARMACOL 2008 155 2 170-184
38. 974308 Vitamin E deficiency accelerates nitrate tolerance via a decrease in cardiac P450 expression and increased oxidative stress. Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S FREE RADIC BIOL MED 2006 40 5 808-816
39. +/- mice. Mollnau H, Wenzel P, Oelze M, Treiber N, Pautz A, Schulz E, Schuhmacher S, Reifenberg K, Stalleicken D, Scharffetter-Kochanek K, Kleinert H et al BMC CARDIOVASC DISORD 2006 6 44
40. 974312 Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Moncada S, Herman AG, Higgs EA, Vane JR THROMB RES 1977 11 3 323-344
41. 974316 Inhibition of nitrate tolerance without reducing vascular response during eccentric dosing of nitrates. Morii H, Naito N, Nakano K, Kanamasa K HYPERTENS RES 2006 29 10 797-804
42. 974327 Nitrate tolerance, oxidative stress, and mitochondrial function: Another worrisome chapter on the effects of organic nitrates. Parker JD J CLIN INVEST 2004 113 3 352-354
43. 974337 Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase. Ramachandran N, Root P, Jiang XM, Hogg PJ, Mutus B PROC NATL ACAD SCI USA 2001 98 17 9539-9544
44. 974347 Inhibition of human platelet aggregation by nitric oxide donor drugs: Relative contribution of cGMP-independent mechanisms. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL BIOCHEM BIOPHYS RES COMMUN 2000 279 2 412-419
45. 974348 Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase 2 downregulation. Szocs K, Lassegue B, Wenzel P, Wendt M, Daiber A, Oelze M, Meinertz T, Munzel T, Baldus S J MOL CELL CARDIOL 2007 42 6 1111-1118
46. 974350 Biotransformation of glyceryl trinitrate by blood platelets as compared to vascular smooth muscle cells. Weber AA, Neuhaus T, Seul C, Dusing R, Schror K, Sachinidis A, Vetter H EUR J PHARMACOL 1996 309 2 209-213
47. 974354 Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. Zai A, Rudd MA, Scribner AW, Loscalzo J J CLIN INVEST 1999 103 3 393-399
48. 974680 Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW J AM COLL CARDIOL 2000 36 1 25-31
49. 975906 Exogenous in vivo NO-donor treatment preserves p53 levels and protects vascular cells from apoptosis. Duran X, Vilahur G, Badimon L ATHEROSCLEROSIS 2008:doi:10.1016/j.atherosclerosis.2008.11.016
50. 976467 Profile and Pipeline. Lacer SA COMPANY WORLD WIDE WEB SITE 2009 January 14
51. 977578 British Heart Foundation: Coronary heart disease statistics 2006. Allender S, Peto V, Scarborough P, Boxer A, Rayner M COMPANY PUBLICATION 2006 May 30
52. 977580 Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Task Force of the European Society of Cardiology EUR HEART J 1997 18 3 394-413
53. 977581 Mechanisms of plaque vulnerability and rupture. Shah PK J AM COLL CARDIOL 2003 41 4 Suppl S 15S-22S
54. 977586 Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Verheggen PW, de Maat MP, Cats VM, Haverkate F, Zwinderman AH, Kluft C, Bruschke AV EUR HEART J 1999 20 8 567-574
55. 977595 Recent developments in nitric oxide donor drugs. Miller MR, Megson IL BR J PHARMACOL 2008 151 3 305-321
56. 977596 Coronary steal-induced increase in myocardial infarct size after pharmacologic coronary vasodilation. Warltier DC, Gross GJ, Brooks HL AM J CARDIOL 1980 46 1 83-90
57. 977598 Nitrate therapy: Is there an optimal substance and formulation? Fung HL EUR HEART J 1991 12 Suppl A 9-12
58. 977601 Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. Thadani U, Ripley TL EXPERT OPIN DRUG SAFETY 2007 6 4 385-396
59. 977602 Continuous administration of organic nitrate decreases hepatic cytochrome P450. Minamiyama Y, Takemura S, Yamasaki K, Hai S, Hirohashi K, Funae Y, Okada S J PHARMACOL EXP THER 2004 308 2 729-735
60. 977603 Rationale for intermittent nitrate therapy. Amsterdam EA AM J CARDIOL 1992 70 17 55G-59G
61. 977604 Oxidative stress and mitochondrial aldehyde dehydrogenase activity: A comparison of pentaerythritol tetranitrate with other organic nitrates. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M, Kleschyov AL, Stalleicken D, Ullrich V, Mulsch A et al MOL PHARMACOL 2004 66 6 1372-1382
62. 977605 Antioxidant vitamin supplements and cardiovascular disease. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL CIRCULATION 2004 110 5 637-641